1·Revenues are also down, with a handful of large biotechs like Amgen (AMGN) making the lion's share of money while the majority of biotechs struggle to raise funds, especially for early stage projects.
营收也出现下滑，安进(Amgen)等少数几个大型生物技术公司掳走了大部分资金，而其他绝大多数的生物技术公司则面临着筹资困难，处于早期阶段的项目更是如此。
2·He cites in evidence a drug trial by Amgen, a biotech giant, where the researchers concluded that the drug was not effective.
Grove博士举出了这样的一个例子：那是一个由生物技术界的巨头——安进公司所进行的一项药品实验。在这项实验里，研究人员总结道，该药品并不有效。
3·Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
4·Because some patents were not granted until years after Amgen applied, the patent protection could extend until 2015, longer than the 20 years contemplated by patent law.
由于一些专利在安进公司申请后好几年还没有被批准，因此这个专利保护将延长到2015年，超过了专利法规定的20年。
5·Amgen said it would present some new evidence, including information showing that more cancer patients are now needing blood transfusions.
安进表示将提供一些新的证据，包括如今需要输血的癌症患者正在增多等信息。